Firms unite to develop antibiotics against drug-resistant bacteria

09/12/2013 | Pharmaceutical Business Review Online

Swiss firm Debiopharm Group and TCG Lifesciences, a contract research services company, agreed to jointly develop antibiotics against drug-resistant bacteria. Debiopharm will fund the collaboration and share its drug development expertise. TCG's "extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348," Debiopharm President Rolland-Yves Mauvernay said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX